Plain-English translation of NCT07102628 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new cholesterol-lowering medication called , given as an injection in the hospital during or shortly after a heart attack. Researchers want to see if starting this medication right away—before you leave the hospital—can reduce cholesterol levels and help protect your heart in the long term. Half of the participants will receive the medication, and half will receive a placebo (a dummy injection) alongside standard heart attack treatment.
After a heart attack, cholesterol control is critical to prevent another heart event. Some people don't reach safe cholesterol levels with current medications alone, and this trial is testing whether this medication can work faster and more effectively when started immediately during the hospital stay.
You likely qualify if…
You likely don't qualify if…
You'll receive a screening visit within a week of being admitted to the hospital, and then a randomization visit (where you're assigned to receive either the medication or placebo) before you're discharged. You'll receive either the new medication or a matching placebo as a single subcutaneous injection on your first study day. The study then continues for 150 days with scheduled phone calls to check on your safety, plus follow-up calls for 30 days after the main study period ends.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
Australia
Canada
China